TY - JOUR
T1 - Tolerated Re-Challenge of Immunotherapy in a Patient with ICI Associated Myocarditis
T2 - A Case Report and Literature Review
AU - Shalata, Walid
AU - Attal, Zoé Gabrielle
AU - Shhadi, Rajeh
AU - Abu Salman, Amjad
AU - Abu Jama, Ashraf
AU - Shalata, Sondos
AU - Halumi, Kais
AU - Yakobson, Alexander
N1 - Publisher Copyright:
© 2023 by the authors.
PY - 2023/11/1
Y1 - 2023/11/1
N2 - Many different types of cancer can be treated with immunotherapy drugs called immune checkpoint inhibitors (ICIs). These drugs have altered the landscape of cancer treatment options since they function by triggering a stronger immune response to malignancy. As expected, ICIs’ modification of immune regulatory controls leads to a wide range of organ/gland-specific immune-related side effects. These adverse effects are uncommonly deadly and typically improve by discontinuing treatment or administering corticosteroid drugs. As a result of a number of factors—including a lack of specificity in the clinical presentation, the possibility of overlap with other cardiovascular and general medical illnesses, difficulties in diagnosis, and a general lack of awareness—the true incidence of ICI-associated myocarditis is likely underestimated. Currently, protocols for the surveillance, diagnosis, or treatment of this condition are unclear. Several questions remain unanswered, such as how to best screen for this rare toxin, what tests should be run on patients who are suspected of having it, how to treat myocarditis once it has developed, and who is at most risk. In this article, we provide a case study of ICI-associated myocarditis and explain its key characteristics and treatment options.
AB - Many different types of cancer can be treated with immunotherapy drugs called immune checkpoint inhibitors (ICIs). These drugs have altered the landscape of cancer treatment options since they function by triggering a stronger immune response to malignancy. As expected, ICIs’ modification of immune regulatory controls leads to a wide range of organ/gland-specific immune-related side effects. These adverse effects are uncommonly deadly and typically improve by discontinuing treatment or administering corticosteroid drugs. As a result of a number of factors—including a lack of specificity in the clinical presentation, the possibility of overlap with other cardiovascular and general medical illnesses, difficulties in diagnosis, and a general lack of awareness—the true incidence of ICI-associated myocarditis is likely underestimated. Currently, protocols for the surveillance, diagnosis, or treatment of this condition are unclear. Several questions remain unanswered, such as how to best screen for this rare toxin, what tests should be run on patients who are suspected of having it, how to treat myocarditis once it has developed, and who is at most risk. In this article, we provide a case study of ICI-associated myocarditis and explain its key characteristics and treatment options.
KW - cardiac toxicity
KW - cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
KW - immune checkpoint inhibitors (ICIs)
KW - immune-related adverse events (IRAE)
KW - inhibitors
KW - myocarditis
KW - programmed cell death protein 1 (PD-1)
KW - programmed death-ligand 1 (PD-L1)
UR - http://www.scopus.com/inward/record.url?scp=85177777575&partnerID=8YFLogxK
U2 - 10.3390/medicina59111946
DO - 10.3390/medicina59111946
M3 - Review article
C2 - 38003995
AN - SCOPUS:85177777575
SN - 1010-660X
VL - 59
JO - Medicina (Lithuania)
JF - Medicina (Lithuania)
IS - 11
M1 - 1946
ER -